Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSPO | P30536 | 3/20 | 0.45 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134683 | 0.91 | TSHR (0.50) | TDP1TSHRKLK1TSPOSLC2A1 | |
| SCHEMBL5135113 | 0.90 | TDP1 (0.49) | TDP1TSHRALDH1A1NPSR1KLK1 | |
| SCHEMBL5135328 | 0.90 | TDP1 (0.58) | TDP1TSHRALDH1A1NPSR1KLK1 | |
| SCHEMBL5136616 | 0.89 | TSHR (0.47) | TDP1TSHRALDH1A1NPSR1KLK1 | |
| SCHEMBL5136868 | 0.87 | KDM4E (0.45) | TDP1TSHRALDH1A1KDM4ENPC1 | |
| SCHEMBL5136230 | 0.87 | TDP1 (0.50) | TDP1TSHRALDH1A1NPSR1KLK1 | |
| SCHEMBL5135087 | 0.86 | TDP1 (0.41) | TDP1TSHRALDH1A1GAA | |
| SCHEMBL5134873 | 0.86 | TDP1 (0.54) | TDP1TSHRALDH1A1NPSR1KLK1 | |
| SCHEMBL5135306 | 0.84 | TDP1 (0.47) | TDP1TSHRALDH1A1NPSR1KLK1 | |
| SCHEMBL5138035 | 0.82 | TDP1 (0.49) | TDP1TSHRALDH1A1NPSR1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148225-B2 | Substituted biaryl amides as C5A receptor modulators | NEUROGEN CORPORATION (US) | 2006-12-12 | — | — | US | claimed |
| EP-1487796-A4 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-05-05 | — | — | US | claimed |
| EP-1487796-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-12-22 | — | — | EP | claimed |
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-03-11 | — | — | US | claimed |
| WO-2003082826-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291621-B2 | Substituted biaryl amides C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7148225-B2 | Substituted biaryl amides as C5A receptor modulators | NEUROGEN CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060178414-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2006-08-10 | — | — | US | disclosed |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-05-05 | — | — | US | disclosed |
| US-6858637-B2 | Treating rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, and bronchial asthma; e.g., 2-Methoxynaphthalene-1-carboxylic acid benzyl-indan-2-yl-amide | NEUROGEN CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | TDP1 4028/4885TSHR 207/4885ALDH1A1 1494/4885 |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | C5AR1, C5AR2, C3AR1 | TDP1 4185/4885TSHR 198/4885ALDH1A1 1680/4885 |
| US-20060178414-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | TDP1 4185/4885TSHR 198/4885ALDH1A1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.